FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CREBBP-PRSS33

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CREBBP-PRSS33
FusionPDB ID: 19379
FusionGDB2.0 ID: 19379
HgeneTgene
Gene symbol

CREBBP

PRSS33

Gene ID

1387

260429

Gene nameCREB binding proteinserine protease 33
SynonymsCBP|KAT3A|MKHK1|RSTS|RSTS1EOS
Cytomap

16p13.3

16p13.3

Type of geneprotein-codingprotein-coding
DescriptionCREB-binding proteinhistone lysine acetyltransferase CREBBPprotein-lysine acetyltransferase CREBBPserine protease 33protease, serine 33serine protease EOS
Modification date2020032920200313
UniProtAcc

Q92793

Main function of 5'-partner protein: FUNCTION: Acetylates histones, giving a specific tag for transcriptional activation (PubMed:24616510). Also acetylates non-histone proteins, like DDX21, FBL, IRF2, MAFG, NCOA3, POLR1E/PAF53 and FOXO1 (PubMed:10490106, PubMed:11154691, PubMed:12738767, PubMed:12929931, PubMed:9707565, PubMed:24207024, PubMed:28790157, PubMed:30540930). Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers (PubMed:14645221). Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER) (PubMed:24939902). Acetylates POLR1E/PAF53, leading to decreased association of RNA polymerase I with the rDNA promoter region and coding region (PubMed:24207024). Acetylates DDX21, thereby inhibiting DDX21 helicase activity (PubMed:28790157). Acetylates FBL, preventing methylation of 'Gln-105' of histone H2A (H2AQ104me) (PubMed:30540930). Functions as a transcriptional coactivator for SMAD4 in the TGF-beta signaling pathway (PubMed:25514493). {ECO:0000269|PubMed:10490106, ECO:0000269|PubMed:11154691, ECO:0000269|PubMed:12738767, ECO:0000269|PubMed:12929931, ECO:0000269|PubMed:14645221, ECO:0000269|PubMed:24207024, ECO:0000269|PubMed:24616510, ECO:0000269|PubMed:24939902, ECO:0000269|PubMed:25514493, ECO:0000269|PubMed:28790157, ECO:0000269|PubMed:30540930, ECO:0000269|PubMed:9707565}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000262367, ENST00000382070, 
ENST00000293851, ENST00000570702, 
ENST00000576886, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score43 X 38 X 17=277782 X 5 X 2=20
# samples 614
** MAII scorelog2(61/27778*10)=-5.50898967694577
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(4/20*10)=1
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: CREBBP [Title/Abstract] AND PRSS33 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CREBBP [Title/Abstract] AND PRSS33 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CREBBP(3929833)-PRSS33(2836122), # samples:3
Anticipated loss of major functional domain due to fusion event.CREBBP-PRSS33 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CREBBP-PRSS33 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CREBBP-PRSS33 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
CREBBP-PRSS33 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
CREBBP-PRSS33 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF.
CREBBP-PRSS33 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
CREBBP-PRSS33 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
CREBBP-PRSS33 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneCREBBP

GO:0000122

negative regulation of transcription by RNA polymerase II

21539536

HgeneCREBBP

GO:0006355

regulation of transcription, DNA-templated

12169688

HgeneCREBBP

GO:0006473

protein acetylation

15273251|24207024|24939902|28790157|30540930

HgeneCREBBP

GO:0016573

histone acetylation

11742995

HgeneCREBBP

GO:0018076

N-terminal peptidyl-lysine acetylation

12435739

HgeneCREBBP

GO:0034644

cellular response to UV

24939902

HgeneCREBBP

GO:0045893

positive regulation of transcription, DNA-templated

11742995

HgeneCREBBP

GO:1990258

histone glutamine methylation

30540930

TgenePRSS33

GO:0006508

proteolysis

12795636

TgenePRSS33

GO:0070528

protein kinase C signaling

12795636



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr16:3929833/chr16:2836122)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CREBBP (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across PRSS33 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000262367CREBBPchr163929833-ENST00000576886PRSS33chr162835172-21148957351245
ENST00000382070CREBBPchr163929833-ENST00000576886PRSS33chr162835172-15082890614204

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000262367ENST00000576886CREBBPchr163929833-PRSS33chr162835172-0.418528620.5814713
ENST00000382070ENST00000576886CREBBPchr163929833-PRSS33chr162835172-0.372106940.62789303

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CREBBP-PRSS33

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CREBBPchr163929833PRSS33chr16283517289536GAGRVGEAAAKSQPQQQRPAALTARP
CREBBPchr163929833PRSS33chr16283517289548QPQQQRPAALTARPRPPPPPPAAAPS
CREBBPchr163929833PRSS33chr16283517289549PQQQRPAALTARPRPPPPPPAAAPSS

Top

Potential FusionNeoAntigen Information of CREBBP-PRSS33 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CREBBP-PRSS33_3929833_2835172.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:05RPRPPPPP0.99950.62291119
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:02RPRPPPPP0.99950.66871119
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:05RPRPPPPPP0.99810.66471120
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:02RPRPPPPPP0.99790.70681120
CREBBP-PRSS33chr163929833chr162835172895HLA-B08:09RPRPPPPPP0.83210.66111120
CREBBP-PRSS33chr163929833chr162835172895HLA-B81:01RPRPPPPPP0.6830.52491120
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:05RPRPPPPPPA0.99980.72571121
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:02RPRPPPPPPA0.99970.75781121
CREBBP-PRSS33chr163929833chr162835172895HLA-B56:01ARPRPPPPPP0.96550.5011020
CREBBP-PRSS33chr163929833chr162835172895HLA-B56:01RPRPPPPPPA0.95940.53921121
CREBBP-PRSS33chr163929833chr162835172895HLA-B81:01RPRPPPPPPA0.94380.65371121
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:05ARPRPPPPPP0.89840.68851020
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:02ARPRPPPPPP0.84660.74611020
CREBBP-PRSS33chr163929833chr162835172895HLA-B82:01RPRPPPPPPA0.84640.55831121
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:05RPRPPPPPPAA10.76271122
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:02RPRPPPPPPAA10.75691122
CREBBP-PRSS33chr163929833chr162835172895HLA-B55:01ARPRPPPPPPA0.99960.52541021
CREBBP-PRSS33chr163929833chr162835172895HLA-B55:01RPRPPPPPPAA0.99920.62831122
CREBBP-PRSS33chr163929833chr162835172895HLA-B81:01RPRPPPPPPAA0.99910.72891122
CREBBP-PRSS33chr163929833chr162835172895HLA-B56:01RPRPPPPPPAA0.99630.65041122
CREBBP-PRSS33chr163929833chr162835172895HLA-B82:01RPRPPPPPPAA0.98710.70911122
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:12RPRPPPPP0.99740.75611119
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:04RPRPPPPP0.9960.65611119
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:12RPRPPPPPP0.99210.78291120
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:04RPRPPPPPP0.98250.69541120
CREBBP-PRSS33chr163929833chr162835172895HLA-B54:01RPRPPPPPP0.96340.55651120
CREBBP-PRSS33chr163929833chr162835172895HLA-B73:01ARPRPPPPP0.81550.87121019
CREBBP-PRSS33chr163929833chr162835172895HLA-B56:04RPRPPPPPP0.70660.51891120
CREBBP-PRSS33chr163929833chr162835172895HLA-B78:01RPRPPPPPP0.48380.6731120
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:12RPRPPPPPPA0.99930.79371121
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:04RPRPPPPPPA0.99610.75711121
CREBBP-PRSS33chr163929833chr162835172895HLA-B54:01RPRPPPPPPA0.98430.66371121
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:04ARPRPPPPPP0.95950.7291020
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:12RPRPPPPPPAA0.99990.79251122
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:04RPRPPPPPPAA0.99990.77771122
CREBBP-PRSS33chr163929833chr162835172895HLA-B42:02RPRPPPPPPAA0.99940.59631122
CREBBP-PRSS33chr163929833chr162835172895HLA-B54:01RPRPPPPPPAA0.99930.77171122
CREBBP-PRSS33chr163929833chr162835172895HLA-B42:01RPRPPPPPPAA0.99880.5881122
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:09RPRPPPPP0.99950.64081119
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:22RPRPPPPP0.99950.66871119
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:22RPRPPPPPP0.99790.70681120
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:09RPRPPPPPP0.99770.6771120
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:26RPRPPPPPP0.77920.52391120
CREBBP-PRSS33chr163929833chr162835172895HLA-B56:02RPRPPPPPP0.70660.51891120
CREBBP-PRSS33chr163929833chr162835172895HLA-B67:01RPRPPPPPP0.42890.86081120
CREBBP-PRSS33chr163929833chr162835172895HLA-B78:02RPRPPPPPP0.41110.69751120
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:09RPRPPPPPPA0.99970.73671121
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:22RPRPPPPPPA0.99970.75781121
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:26ARPRPPPPPP0.9890.52351020
CREBBP-PRSS33chr163929833chr162835172895HLA-B55:02RPRPPPPPPA0.98170.54631121
CREBBP-PRSS33chr163929833chr162835172895HLA-B55:04RPRPPPPPPA0.97660.51431121
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:22ARPRPPPPPP0.84660.74611020
CREBBP-PRSS33chr163929833chr162835172895HLA-B82:02RPRPPPPPPA0.84640.55831121
CREBBP-PRSS33chr163929833chr162835172895HLA-B67:01RPRPPPPPPA0.81610.88241121
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:09RPRPPPPPPAA10.74961122
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:22RPRPPPPPPAA10.75691122
CREBBP-PRSS33chr163929833chr162835172895HLA-B07:26RPRPPPPPPAA0.99910.52421122
CREBBP-PRSS33chr163929833chr162835172895HLA-B55:02RPRPPPPPPAA0.99840.69991122
CREBBP-PRSS33chr163929833chr162835172895HLA-B56:05RPRPPPPPPAA0.99410.56781122
CREBBP-PRSS33chr163929833chr162835172895HLA-B55:04RPRPPPPPPAA0.99380.64091122
CREBBP-PRSS33chr163929833chr162835172895HLA-B67:01RPRPPPPPPAA0.9910.92621122
CREBBP-PRSS33chr163929833chr162835172895HLA-B82:02RPRPPPPPPAA0.98710.70911122
CREBBP-PRSS33chr163929833chr162835172895HLA-B56:05TARPRPPPPPP0.98280.6367920

Top

Potential FusionNeoAntigen Information of CREBBP-PRSS33 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of CREBBP-PRSS33

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
54AALTARPRPPPPPPCREBBPPRSS33chr163929833chr162835172895

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CREBBP-PRSS33

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN54AALTARPRPPPPPP-5.97758-6.09098
HLA-B14:023BVN54AALTARPRPPPPPP-5.15013-6.18543
HLA-B52:013W3954AALTARPRPPPPPP-6.29935-6.41275
HLA-B52:013W3954AALTARPRPPPPPP-6.07479-7.11009
HLA-A24:025HGA54AALTARPRPPPPPP-7.25246-8.28776
HLA-A24:025HGA54AALTARPRPPPPPP-6.23064-6.34404
HLA-B44:053DX854AALTARPRPPPPPP-4.66421-5.69951
HLA-B44:053DX854AALTARPRPPPPPP-4.52141-4.63481
HLA-A02:016TDR54AALTARPRPPPPPP-7.72945-7.84285

Top

Vaccine Design for the FusionNeoAntigens of CREBBP-PRSS33

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CREBBP-PRSS33chr163929833chr1628351721019ARPRPPPPPACAGCACAGTGCCCCTCCCAGAGTGGC
CREBBP-PRSS33chr163929833chr1628351721020ARPRPPPPPPACAGCACAGTGCCCCTCCCAGAGTGGCGAC
CREBBP-PRSS33chr163929833chr1628351721021ARPRPPPPPPAACAGCACAGTGCCCCTCCCAGAGTGGCGACCGC
CREBBP-PRSS33chr163929833chr1628351721119RPRPPPPPGCACAGTGCCCCTCCCAGAGTGGC
CREBBP-PRSS33chr163929833chr1628351721120RPRPPPPPPGCACAGTGCCCCTCCCAGAGTGGCGAC
CREBBP-PRSS33chr163929833chr1628351721121RPRPPPPPPAGCACAGTGCCCCTCCCAGAGTGGCGACCGC
CREBBP-PRSS33chr163929833chr1628351721122RPRPPPPPPAAGCACAGTGCCCCTCCCAGAGTGGCGACCGCTAC
CREBBP-PRSS33chr163929833chr162835172920TARPRPPPPPPATGACAGCACAGTGCCCCTCCCAGAGTGGCGAC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of CREBBP-PRSS33

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LUSCCREBBP-PRSS33chr163929833ENST00000262367chr162835172ENST00000576886TCGA-33-4587

Top

Potential target of CAR-T therapy development for CREBBP-PRSS33

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CREBBP-PRSS33

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CREBBP-PRSS33

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneCREBBPC4551859RUBINSTEIN-TAYBI SYNDROME 112CLINGEN;GENOMICS_ENGLAND;UNIPROT
HgeneCREBBPC0035934Rubinstein-Taybi Syndrome6CLINGEN;CTD_human
HgeneCREBBPC0033578Prostatic Neoplasms2CTD_human
HgeneCREBBPC0376358Malignant neoplasm of prostate2CTD_human
HgeneCREBBPC4511003Acute myeloid leukemia with t(8;16)(p11;p13) translocation2ORPHANET
HgeneCREBBPC0005684Malignant neoplasm of urinary bladder1CTD_human
HgeneCREBBPC0005695Bladder Neoplasm1CTD_human
HgeneCREBBPC0007137Squamous cell carcinoma1CTD_human
HgeneCREBBPC0007138Carcinoma, Transitional Cell1CTD_human
HgeneCREBBPC0010606Adenoid Cystic Carcinoma1CTD_human
HgeneCREBBPC0011573Endogenous depression1PSYGENET
HgeneCREBBPC0024301Lymphoma, Follicular1CTD_human
HgeneCREBBPC0036920Sezary Syndrome1CTD_human
HgeneCREBBPC0079745Lymphoma, Large-Cell, Follicular1CTD_human
HgeneCREBBPC0079758Lymphoma, Mixed-Cell, Follicular1CTD_human
HgeneCREBBPC0079765Lymphoma, Small Cleaved-Cell, Follicular1CTD_human
HgeneCREBBPC0149925Small cell carcinoma of lung1CTD_human
HgeneCREBBPC0152013Adenocarcinoma of lung (disorder)1CTD_human
HgeneCREBBPC0279626Squamous cell carcinoma of esophagus1CTD_human
HgeneCREBBPC1862939AMYOTROPHIC LATERAL SCLEROSIS 11CTD_human
HgeneCREBBPC1862941Amyotrophic Lateral Sclerosis, Sporadic1CTD_human
HgeneCREBBPC1956130Lymphoma, Follicular, Grade 11CTD_human
HgeneCREBBPC1956131Lymphoma, Follicular, Grade 31CTD_human
HgeneCREBBPC1956132Lymphoma, Follicular, Grade 21CTD_human
HgeneCREBBPC4551993Amyotrophic Lateral Sclerosis, Familial1CTD_human